July 2026 Research Update

This month added longer-view, real-world reassurance that enzyme replacement therapy (ERT) can line up with lasting improvements in Gaucher disease measures that matter to day-to-day health, especially blood counts and organ enlargement. The largest dataset followed people for up to 15 years and reported that many early gains were not only reached within the first few years, but also maintained later on. A separate small report added a limited but concrete data point about ERT being continued during pregnancy without reported complications in one person with Gaucher disease. [1] [2]

In 204 patients treated across 13 centers in India, blood counts, liver and spleen size, a Gaucher-related blood marker, growth measures, and bone pain improved most noticeably within 1 to 5 years and were reported as sustained through 10 to 15 years of follow-up. The same cohort reported that starting ERT earlier was linked to a larger blood-count response as early as the first year. This builds a clearer picture that many of the benefits people hope for from ERT, when they occur, may be seen relatively early and can persist for years in routine follow-up. [1]

Pregnancy-specific information was limited, but one single-center series of inherited metabolic disorders included one woman with Gaucher disease who continued ERT throughout pregnancy without reported complications. Because this was only one Gaucher pregnancy within a small mixed-diagnosis group, it does not answer broader questions (such as outcomes across different Gaucher types or different ERT products), but it shows how some real-world teams have managed ERT continuity during pregnancy. [2]

For patients and caregivers, these studies mainly add context about what has been observed over long stretches of time in treated groups, rather than introducing new treatment options. The long follow-up report supports the idea that improvements in blood counts, organ size, and bone pain can be seen within a few years and may be maintained for many years, while also noting that earlier start was linked to stronger early blood-count changes. The pregnancy information is early and very limited, but it contributes one documented example of ERT being continued through pregnancy without complications in that individual, which may matter to families looking for published experience even when it is not yet comprehensive. [1] [2]

This month, two human studies looked at risks that can matter alongside Gaucher disease: serious infections and later-life brain changes tied to GBA genetics. The COVID-19 study found that lysosomal disorders as a broad group had higher hospitalization odds, but Gaucher disease was not one of the groups with a clearly higher risk after adjustment. Separately, a study in older adults without obvious Parkinson symptoms reported that one common GBA variant (E326K) was linked to more Lewy body pathology, and to lower cognitive scores among people who had Lewy bodies. [3] [4]

Using harmonized U.S. electronic health records, researchers compared COVID-19 outcomes in 5,460 people with lysosomal disorders against matched controls and observed higher hospitalization odds for lysosomal disorders overall (OR 1.86). When they looked at specific disorder groups, Gaucher disease was not reported as significantly elevated after adjustment, and one-year survival after hospitalization was similar between the lysosomal disorder group and controls (82.1% vs 82.0%). This helps separate broad risks seen in some lysosomal disorders from what was seen for Gaucher disease specifically in this dataset. [3]

In a separate cohort of 845 aging individuals, E326K carriers had a higher prevalence of Lewy body pathology than T369M carriers based on postmortem brain assessment. Among those who were Lewy body-positive, E326K carriers had lower MMSE scores than Lewy body-negative non-carriers, and they also had a modest decrease compared with T369M carriers. This adds to the picture that not all GBA variants behave the same way when it comes to Lewy body-related brain changes, but the authors noted the findings were preliminary and from a single center. [4]

For patients and caregivers, these results mainly help set expectations about what large datasets and aging cohorts are (and are not) showing, rather than changing care today. The COVID-19 study suggests that while some lysosomal disorders had higher hospitalization risk, Gaucher disease did not stand out as clearly higher after adjustment in that analysis, and survival after hospitalization was similar to controls. The GBA variant study may matter more for longer-term research questions about memory and Lewy body-related conditions, because it suggests E326K may be linked to more Lewy body changes and slightly worse cognition when those changes are present, but it does not show what will happen for any one person and needs confirmation in larger groups. [3] [4]

This month had several early research efforts aimed at boosting glucocerebrosidase (GCase) function in different ways: small-molecule chaperones, changing how the cell routes the enzyme, and gene delivery to the brain. Across these studies, GCase activity could be increased in cells or brain tissue, but the work also highlighted that the hard part is not only getting higher enzyme activity, but doing it safely and reliably in the right tissues. A separate report created a patient-derived stem cell line to support future disease modeling. [5] [6] [7] [8]

One medicinal chemistry study designed a new pharmacological chaperone (a small molecule meant to help GCase fold and work better) and reported that the lead compound increased GCase activity in Gaucher mutant cell lines with V394L and L444P variants. The compound also showed stronger binding to GCase and improved selectivity versus a related enzyme, and it was active in cells at about a tenfold lower dose than isofagomine in their experiments. This gives an early signal that new chaperone designs might improve how much functioning enzyme is present inside cells, but these are still laboratory results without human outcome data. [5]

Another lab study used a genome-wide screen in mouse macrophages and identified PLCG2 as a regulator of lysosomal GCase activity. When PLCG2 was depleted, more mutant GCase was transported toward lysosomes, and lysosomal GCase activity and clearance of harmful substrates increased. This matters as a research direction because it points to a potential strategy that focuses on enzyme trafficking (getting more enzyme to the lysosome) rather than changing the enzyme itself. [6]

A separate preclinical gene-therapy delivery study tested AAV9-GBA1 in mice and in cynomolgus monkeys, focusing on the brain. In newborn mice, brain GCase activity increased and the authors reported no widespread safety signals, although neuronal vacuolation was seen at the highest dose. In adult monkeys, brain expression depended strongly on the delivery route, and safety concerns were notable: intraparenchymal delivery produced strong brain expression but had significant clinical signs and brain tissue injury at high dose, while intracisterna magna delivery produced low brain transduction with dorsal root ganglion and spinal cord toxicity. [7]

To support future research, one group created and characterized a human induced pluripotent stem cell line from a person with Gaucher disease carrying two GBA1 variants (p.Arg87Trp and p.Arg296Gln). The cells showed stem-cell-like features, could form the three basic cell lineages, and had a normal chromosome pattern. This type of tool can help researchers study Gaucher biology in human-derived cells, but it does not directly test a treatment. [8]

For patients and caregivers, these studies are mainly early research rather than evidence about current care. The chaperone and trafficking studies show that GCase activity can be increased in cell systems, which helps clarify that multiple biological routes might be used to raise enzyme function, but it remains unknown whether any of these approaches will translate into safe and meaningful benefits in people. The gene-delivery study helps clarify that getting GBA1 into the brain can produce strong enzyme signals in some settings, while also underlining that delivery route and safety limits are major open questions, especially based on the toxicity findings in monkeys. The new patient-derived stem cell line is a research resource that may support future testing, but it is not itself a therapy result. [5] [6] [7] [8]

This month included one case report that does not change what is known about Gaucher biology, but it puts a spotlight on the real-world challenge of reaching a confirmed diagnosis in some settings. The case describes a child with signs strongly suggestive of Gaucher disease, where confirmatory enzyme testing took time to return. The report illustrates how health-system factors, not only the disease itself, can shape the course of care. [9]

In the reported case, a 4-year-old boy had enlarged liver and spleen and low blood counts, and bone marrow testing showed foam cells resembling Gaucher cells. An enzyme assay later confirmed glucocerebrosidase deficiency, but the child died before the result was received, 84 days after admission. The authors emphasized diagnostic delays related to limited resources. [9]

For families, this case mainly adds a concrete example of how delays in specialized testing can matter, especially in places with limited laboratory access. Because it is a single case, it cannot be used to estimate risk for other children with Gaucher disease, and it does not show what would happen with timely diagnosis or specific treatments. It does help clarify that suspected Gaucher disease may require confirmatory enzyme testing that is not equally available everywhere, which can affect the timing of next steps in care. [9]